Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, and University Hospital Ulm, Ulm, Germany.
Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.
Front Immunol. 2021 Dec 14;12:771449. doi: 10.3389/fimmu.2021.771449. eCollection 2021.
The loci are closely linked to the gene. Mismatches in these loci occur with a frequency of about 8%-12% in otherwise 10/10 HLA-matched transplant pairs. There is preliminary evidence that these disparities may associate with increased acute graft-versus-host disease (GvHD) rates. The aim of this study was to analyze a large cohort of German patients and their donors for compatibility and to correlate the matching status with the outcome of unrelated hematopoietic stem cell transplantation (uHSCT). To this end, 3,410 patients and their respective donors were and typed by amplicon-based next-generation sequencing (NGS). All patients included received their first allogeneic transplant for malignant hematologic diseases between 2000 and 2014. Mismatches in the antigen recognition domain (ARD) of genes were correlated with clinical outcome. incompatibility was seen in 12.5% (n = 296) and 17.8% (n = 185) of the 10/10 and 9/10 HLA-matched cases, respectively. mismatches in the ARD associated with a worse overall survival (OS), as shown in univariate (5-year OS: 46.1% vs. 39.8%, log-rank p = 0.038) and multivariate analyses [hazard ratio (HR) 1.25, 95% CI 1.02-1.54, p = 0.034] in the otherwise 10/10 HLA-matched subgroup. The worse outcome was mainly driven by a significantly higher non-relapse mortality (HR 1.35, 95% CI 1.05-1.73, p = 0.017). In the 9/10 HLA-matched cases, the effect was not statistically significant. Our study results suggest that mismatches within the ARD of genes significantly impact the outcome of otherwise fully matched uHSCT and support their consideration upon donor selection in the future.
这些基因座与基因紧密连锁。在其他情况下,10/10 HLA 匹配的移植对中,这些基因座的错配频率约为 8%-12%。有初步证据表明,这些差异可能与急性移植物抗宿主病(GvHD)发生率增加有关。本研究的目的是分析一大群德国患者及其供者的相容性,并将配型状态与无关造血干细胞移植(uHSCT)的结果相关联。为此,对 3410 名患者及其各自的供者进行了基于扩增子的下一代测序(NGS)的和型。所有纳入的患者均在 2000 年至 2014 年间接受了首次异基因移植治疗恶性血液病。基因抗原识别域(ARD)中的错配与临床结果相关。在 10/10 和 9/10 HLA 匹配的病例中,分别有 12.5%(n=296)和 17.8%(n=185)存在不相容性。ARD 中的错配与总体生存(OS)较差相关,单因素分析(5 年 OS:46.1%对 39.8%,log-rank p=0.038)和多因素分析[风险比(HR)1.25,95%置信区间 1.02-1.54,p=0.034]均显示,在其他情况下 10/10 HLA 匹配的亚组中。较差的结果主要是由显著较高的非复发死亡率驱动的(HR 1.35,95%置信区间 1.05-1.73,p=0.017)。在 9/10 HLA 匹配的病例中,这种影响没有统计学意义。我们的研究结果表明,基因 ARD 内的错配显著影响其他完全匹配的 uHSCT 的结果,并支持在未来的供者选择中考虑这些错配。